Islet amyloid and type 2 diabetes mellitus

New England Journal of Medicine

Volumn 343, Issue 6, 2000, Pages 411-419

  Höppener, Jo W M ^a   Ahrén, Bo ^b   Lips, Cornelis J M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; INSULIN;

AMINO ACID SEQUENCE; ARTICLE; GLUCOSE METABOLISM; HISTOPATHOLOGY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN SYNTHESIS; SEQUENCE HOMOLOGY;

AMYLOID; AMYLOIDOSIS; ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; ISLETS OF LANGERHANS; MICE; MICE, TRANSGENIC; PANCREATIC DISEASES;

EID: 0034632806     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM200008103430607     Document Type: Article

References (56)

1. The relation of diabetes mellitus to lesions of the pancreas: Hyaline degeneration of the islands of Langerhans
2. A novel peptide in the calcitonin gene related peptide family as an amyloid fibril protein in the endocrine pancreas
3. Amyloid and polypeptide hormones: What is their relationship?
4. Islet amyloid polypeptide: Identification and chromosomal localization of the human gene
5. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
6. Amyloid deposits and amyloidosis: The β-fibrilloses
7. Islet amyloid polypeptide: Pinpointing amino acid residues linked to amyloid fibril formation
8. Human islet amyloid polypeptide transgenic mice as a model of non-insulin-dependent diabetes mellitus (NIDDM)
9. Amyloidosis: A review of recent diagnostic and therapeutic developments
10. Common core structure of amyloid fibrils by synchroton X-ray diffraction
11. Amyloid P component: A critical review
12. Islet amyloid: A long-recognized but underappreciated pathological feature of type 2 diabetes
13. Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene
14. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: Problems and prospects
15. Pancreatic beta-cell dysfunction as the primary genetic lesion in NIDDM: Evidence from studies in normal glucose-tolerant individuals with a first-degree NIDDM relative
16. Type 2 diabetes: When insulin secretion fails to compensate for insulin resistance
17. Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus
18. Non-linkage of the islet amyloid polypeptide gene with type 2 (non-insulin-dependent) diabetes mellitus
19. Islet amyloid polypeptide (amylin): No evidence of an abnormal precursor sequence in 25 type 2 (non-insulin-dependent) diabetic patients
20. Role of S20G mutation of amylin gene in insulin secretion, insulin sensitivity, and type II diabetes mellitus in Taiwanese patients
21. 20-29
22. Chronic overproduction of islet amyloid polypeptide/amylin in transgenic mice: Lysosomal localization of human islet amyloid polypeptide and lack of marked hyper-glycaemia or hyperinsulinaemia
23. Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse
24. Formation of islet amyloid fibrils in beta-secretory granules of transgenic mice expressing human islet amyloid polypeptide/amylin
25. Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide
26. Molecular physiology of the islet amyloid polypeptide (IAPP)/amylin gene in man, rat, and transgenic mice
27. Extensive islet amyloid formation is induced by development of type II diabetes mellitus and contributes to its progression: Pathogenesis of diabetes in a mouse model
28. IAPP/amylin gene transcriptional control region: Evidence for negative regulation
29. The insulin and islet amyloid polypeptide genes contain similar cell-specific promoter elements that bind identical beta-cell nuclear complexes
30. Intra- and extracellular amyloid fibrils are formed in cultured pancreatic islets of transgenic mice expressing human islet amyloid polypeptide
31. Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide
32. Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide
33. Longitudinal studies on the development of diabetes in individual Macaca nigra
34. Pancreatic islet cell toxicity of amylin associated with type-2 diabetes mellitus
35. Different sensitivity to the cytotoxic action of IAPP fibrils in two insulin-producing cell lines, HIT-T15 and RINm5F cells
36. Induction of apoptosis by human amylin in RINm5F islet β-cells is associated with enhanced expression of p53 and p21(WAF1/CIP1)
37. Intracellular amyloidogenesis by human islet amyloid polypeptide induces apoptosis in COS-1 cells
38. Prolonged exposure of pancreatic beta cells to raised glucose concentrations results in increased cellular content of islet amyloid polypeptide precursors
39. Pore formation by the cytotoxic islet amyloid polypeptide amylin
40. Promotion of beta-structure by interaction of diabetes associated polypeptide (amylin) with phosphatidylcholine
41. Sulfate content and specific glycosaminoglycan backbone of perlecan are critical for perlecan's enhancement of islet amyloid polypeptide (amylin) fibril formation
42. The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles
43. Differences in amyloid deposition in islets of transgenic mice expressing human islet amyloid polypeptide versus human islets implanted into nude mice
44. β-Cell granule peptides affect human islet amyloid polypeptide (IAPP) fibril formation in vitro
45. Investigation of the effects of antisense oligodeoxynucleotides to islet amyloid polypeptide mRNA on insulin release, content and expression
46. Reduction of islet amyloid expression and basal secretion by adenovirus-mediated delivery of amylin antisense cDNA
47. Effect of insulin treatment on circulating islet amyloid polypeptide in patients with NIDDM
48. Treatment with metformin in NIDDM patients lowers plasma amylin level
49. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus
50. The Lumleian Lecture: C-reactive protein and amyloidosis: From proteins to drugs?
51. Anti-amyloid drugs: Potential in the treatment of diseases associated with aging
52. Disaggregation of Alzheimer β-amyloid by site-directed mAb
53. β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy
54. Transgenic over-expression of human islet amyloid polypeptide inhibits insulin secretion and glucose elimination after gastric glucose gavage in mice
55. Increased insulin secretion and glucose tolerance in mice lacking islet amyloid polypeptide (amylin)
56. Changes in amylin and amylin-like peptide concentrations and β-cell function in response to sulfonylurea or insulin therapy in NIDDM